A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG).
Glioma
Gliomas are a group of brain tumors that arise from glial cells, a type of support cell of the central nervous system, or CNS, which comprises the brain and spinal cord. They make up about one-quarter of all tumors that start in the brain (primary brain tumors), occurring in about 6.6 per 100,000 people every year. They also account for more than 80% of all malignant, or cancerous, brain tumors.
Treatment for gliomas, a diverse group of tumors that form in the brain and spinal cord, can involve a variety of approaches, including surgery, radiation therapy, and chemotherapy, as well as a range of supportive treatments.
News
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The…
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions…
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning…
A team of scientists at the University of Cincinnati Cancer Center is embarking on a series of tests to evaluate an experimental immune-modulating treatment strategy…
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio.
